Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Patent
1995-03-27
1996-12-31
Smith, Lynette F.
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
4241841, 4241881, 4242041, 530324, A61K 3921, A61K 3912, A61K 3814, C07K 500
Patent
active
055891756
ABSTRACT:
In accordance with the present invention, novel peptides corresponding to epitopes of human immunodeficiency virus-1 gp120 protein and analogues and homologs thereof are provided. These peptides can be utilized alone or in combination, uncoupled or coupled to other molecules or substrates. The peptides are useful in immunization against human immunodeficiency virus infection and in production of polyclonal and monoclonal antibodies.
REFERENCES:
patent: 4943628 (1990-07-01), Rosen et al.
patent: 5019387 (1991-05-01), Haynes et al.
Haynes, 1993, "Scientific and Social issues . . . " Science 260:1279-1286.
Fox, 1994, "No Winners against AIDS" Biotechnology 12: 128.
A. Vahlne, et al. "Immunisation of Monkeys With Synthetic Peptides Disclose Conserved Areas on gp120 of Human Immunodeficiency Virus Type 1 Associated with Cross-Neutralizing Antibodies and T-cell Recognition", Proceedings of The National Academy of Sciences, vol. 88, No. 23, Dec. 1, 1991, pp. 10744-10748.
D. F. Nixon, et al. "Cellular and Humoral Antigenic Epitopes in HIV and SIV", Immunology, vol. 76, No. 4, Aug. 1992, pp. 515-534.
Chanh, et al., 1986 "Induction of anti-HIV Neutralizing Antibodies by Synthetic Peptides". EMBOJ 5(11):3065-3071.
Dreesman, 1988 "Experimental Gp 120 and Gp 41 AIDS Vaccines" Meeting Abstract, 7th Summer Symposium in Mol. Biol. . . . Jul. 27-29, 1988 University Park, PA. p. 42.
Allan et al., "Major Glycoprotein Antigens that Induce Antibodies in AIDs Patients Are Encoded by HTLV-III", Science, 228:1091-1094 (1985).
Barin et al., "Virus Envelope Protein of HTLV-III Represents Major Target Antigen for Antibodies in AIDs Patients", Science, 228:1094-1096 (1985).
Cabradilla et al., "Serodiagnosis of Antibodies to the Human AIDs Retrovirus With a Bacterially Synthesized env Polypeptide", Biotechnology, 4:128:133 (1986).
Chang et al., "Detection of Antibodies to Human T-Cell Lymphotrophic Virus III (HTLV-III) With an Immunoassay Employing a Recombinant Escherichia coli--Derived Viral Antigenic Peptide", Biotechnology, 3:905-909 (1985).
Kennedy et al., "Antiserum to a Synthetic Peptide Recognizes the HTLV-III Envelope Glycoprotein", Science, 231:1556-1559 (1986).
Lerner et al., "In, The Biology of Immunological Disease: A Hospital Practice Book", (Dixon and Fisher eds.) pp. 331-338 (1983).
Lerner, "Antibodies of Predetermined Specificity in Biology and Medicine", Adv. Immunol., 36:1-44 (1984).
Van Regenmortel, "Synthetic Peptides as Viral Vaccines", Ann. Inst. Pasteur/Virol. 137E:497-528 (1986).
Erickson and Merrifield in: The Proteins, 3rd Ed. vol. 2, Academic Press, N.Y., Chapter 3 pp. 255-527 (1976).
Cianciolo et al., "Macrophage Accumulation in Mice is Inhibited by Low Molecular Weight Products from Murine Leukemia Viruses", J. Immunol., 124-2900-2905 (1980).
Cianciolo et al., "Inhibition of Lymphocyte Proliferation by a Synthetic Peptide Homologous to Retroviral Envelope Proteins", Science, 230:453-455, (1985).
Steward et al., "Synthetic Peptides: A Next Generation of Vaccines?", Immunol. Today, 8:51-58 (1987).
Berman et al., "Protection of Chimpanzees from Infection by HIV-1 after Vaccination With Recombinant Glycoprotein gp120 but Not gp160", Nature 345:622-625 (1990).
Bolognesi, "HIV Antibodies and Vaccine Design", AIDS 1989 3:S111-S118.
Muesing et al., "Nucleic Acid Structure and Expression of the Human AIDs/Lymphadenopathy Retrovirus", Nature, 313:450-458, (1985).
Sanchez et al., "Recombinant System for Overexpression of Cholera Toxin B Subunit In Vibrio cholerae as a Basis For Vaccine Development", Proc. Natl. Acad Sci USA, 86:481-485 (1989).
Takahashi et al., "Induction of CD8.sup.+ Cytotoxic T Cells by Immunization With Purified HIV-1 Envelope Protein In ISCOMs", Nature, 344:873-875 (1990).
Bergot et al., "Utility of Trifluromethane Sulfonic Acid as a Cleavage Reagent in Solid Phase Peptide Synthesis", Applied Biosystems User Bulletin, Peptide Synthesizer, Issue No. 16, Sep. 2, 1986.
Jeansson et al., "Elimination of Mycoplasmas from Cell Cultures Utilizing Hyperimmune Sera", Ex. Cell Res., 161:181-188 (1985).
Ho et al., Science, 239:1021-1023 (1988).
Neurath, et al., 1990, "B Cell Epitope Mapping of Human, . . . " J. General Virology 71:85-95.
Modrow et al., 1989, "Use of Synthetic Oligopeptides in Identification . . . " J. Acquired Immune Deficiency Syndrome 2:21-27.
Brown, "AIDS Vaccine Trials Viewed With Caution" The Washington Post Newspaper Jun. 10, 1993.
Ed. Dani bolognesi, "Hiv binding to the CD4 molecule: conformation dependence and binding inhibition studies", J. S. Mc Dougal et al., 1988, Human Retroviruses, Cancer and AIDS, pp. 269-281.
Chemical Abstracts, vol. 111, No. 7, 14 Aug. 1989, (Columbus, Ohio, US), Palker, Thomas J et al.: "Polyvalent hyman immunodeficiency virus synthetic immunogen comprised of envelope gp120 T helper cell sites and B cell neutralization epitopes", see p. 553.
Cohen, 1993, "Jitters Jeopardize AIDS Vaccine Trials" Science 262: 980-981.
Horal Peter
Jeansson Stig
Rymo Lars
Svennerholm Bo
Vahlne Anders
Smith Lynette F.
Syntello Vaccine Development KB
LandOfFree
Peptides for induction of neutralizing antibodies against human does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Peptides for induction of neutralizing antibodies against human , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptides for induction of neutralizing antibodies against human will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1140182